Product
XMT-2056
1 clinical trial
6 indications
Indication
Breast Cancer (HER2-positive)Indication
HER2-positive Gastric CancerIndication
ErBb2 positive Colorectal CancerIndication
HER2-positiveIndication
HER2-Low Breast CancerIndication
NSCLCClinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2Status: Recruiting, Estimated PCD: 2027-04-01